Skip main navigation

£199.99 £139.99 for one year of Unlimited learning. Offer ends on 28 February 2023 at 23:59 (UTC). T&Cs apply

Find out more

How do we treat Candidaemia?

How do we treat candidaemia? This articles gives example of treatment options for candidaemia.

The medical team decide to treat this patient with empirical antifungal therapy. They suspect he may have developed candidaemia during his ICU admission. His background of type 2 diabetes, indwelling central catheter and broad-spectrum antibiotics have increased his risk.

Image of syringe resting on medicine bottle

Blood cultures are taken from the central venous catheter. They are also taken peripherally, with 60ml of blood aspirated in total.

Sputum and urine cultures are also sent.

β-1-3-D-glucan is sent to the laboratory on advice of the Infectious Diseases team.

The team then start an empirical antifungal intravenously for suspected candidaemia.

Just as in the treatment of bacterial sepsis, there are antifungal stewardship factors to consider:

  • Ideally, any diagnostic tests should be sent before antifungal treatment is started
  • Source control is important – if a central venous catheter (or other line) is implicated in the infection, it should be removed as early as possible, if possible
  • Like any antibiotic prescription, antifungal treatment should be regularly reviewed against microbiology results and patient improvement for its effectiveness and continued indication

Guidelines exist on the treatment of candidaemia and other forms of invasive candidosis:

  • The Infectious Diseases Society of America published guidance in 2016

  • The European Society of Clinical Microbiology and Infectious Disease (ESCMID) published guidance in 2012

image of patient hand with intravenous catheter inserted

Both guidelines recommend an intravenous echinocandin as the first line treatment option. This newer group of drugs has supplanted intravenous fluconazole as the drug of choice for a number of reasons:

  • Echinocandins have good activity against the majority of Candida species and resistance is rare
  • Echinocandins have better patient outcomes than alternative drugs with similar microbiological efficacy
  • They are generally safe and well tolerated
  • Drug-drug interactions are rare
  • They have activity against biofilms
  • Echinocandins currently available: caspofungin, micafungin and anidulafungin

Intravenous fluconazole remains an acceptable alternative. However:

  • Consider whether the patient has a risk of azole-resistant Candida (previous antifungal treatment, colonised with resistant species)
  • All clinically relevant Candida isolates should have their azole susceptibility tested
  • Fluconazole does not have activity against biofilms and should not be used if biofilm infection is possible (indwelling medical devices)

Our patient is started on 100mg once daily of intravenous Micafungin. We will revisit this gentleman later in the course…

This article is from the free online

The Role of Antifungal Stewardship

Created by
FutureLearn - Learning For Life

Our purpose is to transform access to education.

We offer a diverse selection of courses from leading universities and cultural institutions from around the world. These are delivered one step at a time, and are accessible on mobile, tablet and desktop, so you can fit learning around your life.

We believe learning should be an enjoyable, social experience, so our courses offer the opportunity to discuss what you’re learning with others as you go, helping you make fresh discoveries and form new ideas.
You can unlock new opportunities with unlimited access to hundreds of online short courses for a year by subscribing to our Unlimited package. Build your knowledge with top universities and organisations.

Learn more about how FutureLearn is transforming access to education